Clinical Trial Update: Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for a multimodal molecular targeted therapy in relapsed or refractory high-risk neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Snippet

Sponsor: University of Regensburg | Conditions: Neuroblastoma Recurrent | Phase 2 | Status: COMPLETED